CN103554087A - 达比加群衍生物、及其制备方法和抗血栓用途 - Google Patents
达比加群衍生物、及其制备方法和抗血栓用途 Download PDFInfo
- Publication number
- CN103554087A CN103554087A CN201310577411.2A CN201310577411A CN103554087A CN 103554087 A CN103554087 A CN 103554087A CN 201310577411 A CN201310577411 A CN 201310577411A CN 103554087 A CN103554087 A CN 103554087A
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- ethyl
- methyl
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical class N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 208000004043 venous thromboembolism Diseases 0.000 claims abstract description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims description 9
- 230000002785 anti-thrombosis Effects 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 230000000452 restraining effect Effects 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims description 2
- 206010014513 Embolism arterial Diseases 0.000 claims description 2
- 206010014522 Embolism venous Diseases 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000583 acetic acid Drugs 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 150000001556 benzimidazoles Chemical class 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 150000004292 cyclic ethers Chemical class 0.000 claims description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229960000448 lactic acid Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 229960004838 phosphoric acid Drugs 0.000 claims description 2
- 229940107700 pyruvic acid Drugs 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 239000004019 antithrombin Substances 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 108090000190 Thrombin Proteins 0.000 abstract description 4
- 229960004072 thrombin Drugs 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 abstract 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 abstract 2
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 30
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 28
- -1 benzimidazoles compound Chemical class 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 14
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000002994 raw material Substances 0.000 description 8
- 239000003868 thrombin inhibitor Substances 0.000 description 8
- 229960003850 dabigatran Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000012265 solid product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000013517 stratification Methods 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 4
- 229940122388 Thrombin inhibitor Drugs 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- JXOQHIPEIGBPRA-UHFFFAOYSA-N CCOC(CCN(C(c(cc1)cc2c1[n](C)c(C(C)Nc(cc1)ccc1C(NC(OCCOCCOC)=O)=N)n2)=O)c1ccccn1)=O Chemical compound CCOC(CCN(C(c(cc1)cc2c1[n](C)c(C(C)Nc(cc1)ccc1C(NC(OCCOCCOC)=O)=N)n2)=O)c1ccccn1)=O JXOQHIPEIGBPRA-UHFFFAOYSA-N 0.000 description 1
- GLXZYOZFTBFKFS-UHFFFAOYSA-N CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C(NC(OC1(CCO3)C3OCC1)=O)=N)n2)=O)c1ccccn1)=O Chemical compound CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C(NC(OC1(CCO3)C3OCC1)=O)=N)n2)=O)c1ccccn1)=O GLXZYOZFTBFKFS-UHFFFAOYSA-N 0.000 description 1
- JXKDKWPHRGHWET-YNFMJHJUSA-N CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C(NC(O[C@@H]1[C@@H](CCO3)[C@@H]3OC1)=O)=N)n2)=O)c1ncccc1)=O Chemical compound CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C(NC(O[C@@H]1[C@@H](CCO3)[C@@H]3OC1)=O)=N)n2)=O)c1ncccc1)=O JXKDKWPHRGHWET-YNFMJHJUSA-N 0.000 description 1
- JXKDKWPHRGHWET-NEFAKALVSA-N CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C(NC(O[C@@H]1[C@H](CCO3)[C@H]3OC1)=O)=N)n2)=O)c1ccccn1)=O Chemical compound CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C(NC(O[C@@H]1[C@H](CCO3)[C@H]3OC1)=O)=N)n2)=O)c1ccccn1)=O JXKDKWPHRGHWET-NEFAKALVSA-N 0.000 description 1
- JXKDKWPHRGHWET-IPTJVUSNSA-N CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C(NC(O[C@H]1[C@H](CCO3)[C@H]3OC1)=O)=N)n2)=O)c1ccccn1)=O Chemical compound CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C(NC(O[C@H]1[C@H](CCO3)[C@H]3OC1)=O)=N)n2)=O)c1ccccn1)=O JXKDKWPHRGHWET-IPTJVUSNSA-N 0.000 description 1
- DSHAZVRBUZDMTD-GHFJDGOLSA-N CCOC(CCN(C(c1ccc2[n](C)c(C(C)Nc(cc3)ccc3C(NC(O[C@@H]3[C@H](CCO4)[C@H]4OC3)=O)=N)nc2c1)=O)c1ccccn1)=O Chemical compound CCOC(CCN(C(c1ccc2[n](C)c(C(C)Nc(cc3)ccc3C(NC(O[C@@H]3[C@H](CCO4)[C@H]4OC3)=O)=N)nc2c1)=O)c1ccccn1)=O DSHAZVRBUZDMTD-GHFJDGOLSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229960000288 dabigatran etexilate Drugs 0.000 description 1
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Abstract
Description
技术领域
本发明涉及药物化学领域,具体涉及一类非肤类的抗凝血酶抑制剂、它们的制备方法以及对凝血酶的抑制作用和抗血栓的作用。
背景技术
在西方社会,血栓栓塞是导致疾病和死亡的主要原因,导致这种症状的重要原因是血凝的过度表达。血栓是由一系列连续的酶解、激活过程中产生凝血因子,生成的纤维蛋白凝块。
凝血酶抑制剂是以一定的凝血因子或凝血酶为目标,通过以抑制或破坏凝血酶的凝血活性,从而破坏凝血的某些过程,抑制血液凝固以及阻断血栓形成。
凝血酶抑制剂发挥凝血作用是因为它与凝血酶里面的纤维蛋白上面特异位点形成特定的结合,阻止了酶解纤维蛋白原的酶解过程,在酶解过程的最后一步过程中阻断凝血瀑布网络,抑制血栓形成。而间接的凝血酶抑制剂主要利用的是与抗凝血酶本身相结合,从而使得凝血酶失活或者抑制凝血酶的产生,它依赖于抗凝血酶才发挥抗凝作用。直接凝血酶抑制剂则直接作用于凝血酶本身,抑制它的活性,而且不需要抗凝血酶辅助,其作用是依赖于凝血酶抑制剂的血药浓度和服用剂量。
达比加群酯(Dabigatran etexilate)含有苯并咪唑和苄基脒结构,是一种人工合成的、新型的直接凝血酶抑制剂。属于达比加群前体药物,是一种非肽类直接凝血酶抑制剂。达比加群酯是德国勃林格殷格翰公司开发出来的,是继华法林普及之后50年来首个上市的新类别口服直接凝血酶抑制剂。于2008年4月在德国和英国率先上市,是成功开发的、具有多种特点的新型抗凝血药物。
达比加群酯口服后,经胃肠的吸收,在体内水解成为具有直接的抗凝血活性达比加群双前药。达比加群双前药结合凝血酶,纤维蛋白上的特异性的结合位点,从而防止纤维蛋白的裂解,阻断凝血过程和血栓形成中的最后一步反应,从发挥可逆的抗凝作用。
目前公开的达比加群酯的专利申请包括WO2012130834,WO2013150545,WO2013144903。
虽然已公开了一系列凝血酶抑制剂,但仍需要开发新的以及具有更好药效的药物,基于此目的,本发明设计了一系列苯并咪唑类化合物。
发明内容
本发明公开一类通式I的苯并咪唑类化合物。
通式I化合物可用下列方法制备:
其中R1,R2和R3的定义同前所述。
由化合物II和氯甲酸酯制备化合物I时,可选用的溶剂有四氢吠喃、丙酮、二氯甲烷、乙睛、四氢吠喃与水的混合溶剂或丙酮与水的混合溶剂;优选四氢吠喃与三乙胺的混合溶剂。
药理实验显示,本发明的化合物不仅可以通过抑制凝血酶达到抗血栓目的,而且对ADP也有一定的抑制作用,从而进一步加强抗血栓效果。因此,本发明的通式I化合物,可用于治疗和预防各种与血栓形成相关的疾病,这些疾病包括动脉血栓栓塞性疾病,静脉血栓栓塞性疾病,以及其它血栓性心脑血管疾病。
本发明的化合物I,药学上可接受的盐也具有与化合物I同样的药理疗效,其中药学上可接受的盐优选为通式I化合物与下列酸形成的盐:盐酸、氢溴酸、硫酸、碳酸、柠檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、马来酸、甲磺酸、苯磺酸、对甲苯磺酸。
本发明还公开了一种药物组合物,其中含有治疗通式I化合物和药学上可接受的载体,这种药物组合物还可以是含有治疗有效量的通式I化合物的药学上可接受的盐和药学上可接受的载体。所述药物组合物可以是普通片剂或胶囊、缓释片剂或胶囊、控释片剂或胶囊、口服液、注射剂等制剂学上常规的制剂形式。
一般地,本发明的通式I化合物用于治疗时,人用剂量范围为0.5mg-2000mg/天。也可根据剂型的不同和疾病严重程度,使用剂量超出该范围。
药效学试验证明,本发明的通式I化合物及其盐不仅可以通过抑制凝血酶到达抗血栓目的,而且对ADP也有一定的抑制作用,从而进一步加强抗血栓效果。
具体实施方式
下面通过实例对本发明作进一步的详细说明,实施例目的在于说明而非限定。
实施例1
3-[[[2-[[[4-[[[(2-甲氧基乙氧基)羰基]氨基]亚氨甲基]苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯(A)的合成与表征
称取(1.0g,2mmol)3-[[[2-[[(4-脒基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯溶于50mL四氢呋喃中。加入(0.22g,2mmol)三乙胺,调节混合体系的pH=8~9之间,搅拌30分钟,滴加(0.277g,2mmol)氯甲酸乙二醇单甲醚酯的四氢呋喃溶液10mL,搅拌2小时。TLC跟踪反应,直至原料消耗完为止,浓缩除去体系中的四氢呋喃,加入20mL饱和食盐水到浓缩后的体系中,再加入10mL二氯甲烷,充分振荡后,静置分层,水相用二氯甲烷(8mL×2)萃取,合并有机相,无水硫酸钠干燥后,抽滤,滤液浓缩,用10mL乙酸乙酯重结晶得到的油状物,得白色固体产品0.91g,收率75.1%,熔点:127.0~129.0℃。
1H NMR(CDCl3,400MHz):1.1(t,3H,CH3),2.4~2.5(t,2H,CH2),3.3(s,3H,CH3),3.5(s,2H,CH2),3.8(t,3H,CH3),3.9(m,2H,CH2),4.1(t,2H,CH2),4.2(t,2H,CH2),4.4~4.5(d,2H,CH2),6.7(d,2H,C6H5),6.8(d,H,C5NH4),7.1(m,2H,C6H5),7.1~7.3(d,H,C5NH4),7.3~7.4(s,H,C6H5),7.4~7.5(t,H,C5NH4),7.7~7.8(d,2H,C6H5),8.3(d,H,C5NH4)。
实施例2
3-[[[2-[[[4-[[[(2-(2-甲氧基乙氧基)乙氧基)羰基]氨基]亚氨甲基]苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯(B)的合成与表征
将(1.0g,2mmol)3-[[[2-[[(4-脒基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯溶于50mL四氢呋喃中。加入(0.22g,2mmol)三乙胺,调节混合体系的pH在8~9之间,滴加(0.38g,2mmol)氯甲酸二乙二醇单甲醚酯的四氢呋喃溶液10mL,搅拌2小时。TLC跟踪反应,至原料消耗完为止,浓缩除去反应体系中的四氢呋喃,向浓缩后体系中加入20mL的饱和食盐水,再加入10mL的二氯甲烷,振荡后静置分层,水相用二氯甲烷(8mL×2)萃取,合并二氯甲烷层,水洗一次后用无水硫酸钠干燥,抽滤,滤液浓缩,油状物用乙酸乙酯重结晶后,得白色固体产品0.73g,收率56.59%,熔点:129.0~131.0℃。
1H NMR(CDCl3,400MHz):1.1~1.2(t,3H,CH3),2.7~2.8(t,2H,CH2),3.3(s,3H,CH3),3.5(m,2H,CH2),3.5(m,2H,CH2),3.6(s,3H,CH3),3.7~3.8(t,2H,CH2),4.0~4.1(m,2H,CH2),4.3(t,2H,CH2),4.4(m,4H,CH2),6.6~6.7(m,3H,C6H5),6.9(t,H,C5NH4),7.0~7.1(d,H,C5NH4),7.2~7.3(m,2H,C6H5),7.6(s,H,C5NH4),7.7(d,2H,C6H5),8.4(d,H,C5NH4)。
实施例3
3-[[[2-[[[4-[[[(己氧基)羰基]氨基]亚氨甲基]苯基]氨基]乙基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯(C)的合成与表征
称取(1.0g,1.95mmol)3-[[[2-[[(4-脒基苯基)氨基]乙基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯溶于50mL四氢呋喃中。加入(0.21g,1.95mol)三乙胺,调节混合体系的pH=8~9之间,滴加(0.115g,0.7mmol)氯甲酸正己酯的四氢呋喃溶液10mL,搅拌2小时。TLC跟踪反应,直至原料消耗完全,浓缩除去反应体系中的四氢呋喃,向浓缩后体系中加入20mL的饱和食盐水,再加入10mL的二氯甲烷,充分振荡后,静置分层,水相再用二氯甲烷(8mL×2)萃取,合并有机层层,无水硫酸钠干燥2小时后抽滤,滤液旋蒸除去二氯甲烷,用10mL的乙酸乙酯重结晶,得白色固体产品0.76g,收率60.8%,熔点:128.0~130.0℃。
1HNMR(CDCl3,400MHz):0.8~0.9(m,3H,CH3),1.1~1.2(t,6H,CH3),1.2(t,4H,CH2),1.2~1.3(t,2H,CH2),1.6(d,2H,CH2),2.7~2.8(t,H,CH2),3.7(s,3H,CH3),4.0~4.1(m,4H,CH2),4.4(t,2H,CH2),4.9(t,H,NH),6.6~6.7(d,3H,C6H5),6.9(m,H,C5NH4),7.1(d,H,C5NH4),7.2~7.3(t,2H,C6H5),7.7(s,H,C5NH4),7.7(d,2H,C6H5),8.4(m,H,C5NH4)。
实施例4
3-[[[2-[[[4-[[[(2-甲氧基乙氧基)羰基]氨基]亚氨甲基]苯基]氨基]乙基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯(D)的合成与表征
称取(0.8g,1.56mmol)3-[[[2-[[(4-脒基苯基)氨基]乙基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯溶于50mL四氢呋喃中。加入(0.17g,1.56mol)三乙胺,调节混合体系的pH=8~9之间,滴加(0.23g,1.60mmol)氯甲酸乙二醇单甲醚酯的四氢呋喃溶液10mL,搅拌2小时。TLC跟踪反应,直至原料消耗完全,浓缩除去反应体系中的四氢呋喃,浓缩后向里面加入20mL的饱和食盐水,再加入10mL二氯甲烷,振荡后静置分层,二氯甲烷(8mL×2)萃取水相,合并有机层,无水硫酸钠干燥2小时后抽滤,滤液经浓缩,再用10mL乙酸乙酯重结晶纯化后,得白色固体产品0.64g,收率66.7%,熔点:129.0~130.0℃。
1H NMR(CDCl3,400MHz):1.1(t,3H,CH3),1.5(d,3H,CH3),1.5(d,H,NH),2.6~2.7(s,2H,CH2),3.2(s,3H,CH3),3.4(s,2H,CH2),3.6(s,H,NH)3.9(m,3H,CH3),4.1(t,2H,CH2),4.3(t,2H,CH2),4.2(t,2H,CH2),4.7~4.8(d,H,NH),6.4(d,2H,C6H5),6.5~6.6(d,H,C5NH4),6.8(t,H,C6H5),6.9(d,H,C5NH4),7.1(d,H,C6H5),7.2(m,H,C5NH4),7.5(d,3H,C6H5),8.3(d,H,C5NH4)。
实施例5
3-[[[2-[[[4-[[[(2-(2-甲氧基乙氧基乙氧基)羰基]氨基]亚氨甲基]苯基]氨基]乙基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯(E)的合成与表征
称取(0.8g,1.56mmol)3-[[[2-[[(4-脒基苯基)氨基]乙基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯溶于50mL四氢呋喃中。加入(0.17g,1.56mol)三乙胺,调节混合体系的pH=8~9之间,滴加(0.30g,1.64mmol)氯甲酸二乙二醇单甲醚酯的四氢呋喃溶液10mL,搅拌2小时。TLC跟踪反应,直至原料消耗完全,浓缩除去体系中的四氢呋喃,浓缩后向里面加入20mL的饱和食盐水,再加入10mL二氯甲烷,充分振荡后,静置分层,水相用二氯甲烷(8mL×2)萃取,合并有机层,无水硫酸钠干燥后抽滤,滤液浓缩,用5mL乙酸乙酯重结晶,得白色固体产品0.53g,收率51.46%,熔点:127.0~129.0℃。
1H NMR(CDCl3,400MHz):0.4(t,3H,CH3),0.7~0.8(m,6H,CH3),1.5(d,2H,CH2),2.7(t,2H,CH2),3.2(s,3H,CH3),3.3~3.4(t,2H,CH2),3.4~3.5(t,2H,CH2),3.6(s,3H,CH3),3.9(t,2H,CH2),4.2(m,2H,CH2),4.3(t,2H,CH2),4.8(d,H,NH),6.4~6.5(d,H,C6H5),6.9(t,H,C5NH4),7.0(t,H,C5NH4),7.2(t,H,C6H5),6.4~6.5(d,H,C5NH4),7.7(d,2H,C6H5),8.4(d,H,C5NH4)。
实施例6
3-[[[2-[[[4-[[[(2-(六氢〔2,3-b]呋喃-3-基氧基))羰基]氨基]亚氨甲基]苯基]氨基]乙基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯(F)的合成与表征
称取1.0g(1.95mmol)3-[[[2-[[(4-脒基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯溶于50mL四氢呋喃中。加入(0.21g,1.95mmol)三乙胺,调节混合体系的pH在8~9之间,滴加0.19g(0.7mmol)羟基六氢呋喃并[2,3-β]呋喃基丁二酰亚胺基碳酸酯的四氢呋喃溶液10mL,搅拌2小时。TLC跟踪反应,直至原料消耗完全,浓缩除去体系中的四氢呋喃,浓缩后向里面加入20mL的饱和食盐水和10mL的二氯甲烷,振荡后静置分层,水相用二氯甲烷(8mL×2)萃取,合并有机相,无水硫酸钠干燥后过滤,滤液浓缩至干,乙酸乙酯重结晶,得白色固体产品0.56g,收率43.1%,熔点:134.0~136.0℃。
1H NMR(CDCl3,400MHz):1.1~1.2(m,6H,CH3),2.7~2.8(t,2H,CH2),3.7(s,3H,CH3),3.8(m,H,CH),3.9(m,2H,CH2),4.0(d,2H,CH2),4.1(m,2H,CH2),4.4(t,2H,CH2),4.9(t,H,CH),5.1~5.2(m,H,NH),5.7(d,H,CH),6.6(d,2H,C6H5),6.7(t,H,C5NH4),6.9~7.0(t,H,C6H5),7.1(m,H,C6H5),7.1(m,H,C6H5),7.3(t,H,C5NH4),7.7(s,H,C5NH4),7.7(d,2H,C6H5),8.4(d,H,C5NH4)。
其它通式I化合物可参照以上合成方法。
其中通式II中,R1为乙基,R2为甲基的化合物合成方法如下,R1,R2为其它取代基也可参考以下合成方法:
3-[[[2-[[(4-脒基苯基)氨基]乙基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯的合成与表征
称取(3.0g,6.22mmol)3-[[[2-[[(4-氰基苯基)氨基]乙基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯溶于干燥的30mL无水乙醇与15mL1,2-二氯乙烷[3]中。升温至35℃后通入干燥氯化氢至饱和后,控温在35℃下搅反应,反应过程中,取样用碱游离萃取后点板,反应8小时后,原料存在,继续通入干燥的氯化氢气体,直至饱和后,继续控温在35℃下反应,5小时后,原料基本反应完全。在干燥的条件下,减压蒸去溶剂,加入无水乙醇40mL,加热溶清后,将体系降至室温,向反应体系缓慢通入干燥后的氨气至饱和,通入氨气的时候体系升温较为剧烈,因为放热剧烈而导致塞子喷出,体系需要要水冷却,待反应放热平稳后,通入足量的氨气使得体系至饱和,控温在35℃下搅拌8小时。抽滤除去生成的氯化铵,水相浓缩至干,用10mL的乙酸乙酯经重结晶,得到白色固体2.2g,收率70.7%。
1H NMR(DMSO,400MHz):1.0~1.1(m,6H,CH3),1.5(s,H,NH),2.7(t,2H,CH2),3.4(m,H,CH),3.7(s,3H,CH3),3.9(m,2H,CH2),4.2(t,2H,CH2),6.7~6.8(m,3H,C6H5),7.1(m,2H,C6H5),7.3~7.5(d,2H,C5NH4),7.4~7.5(m,2H,C6H5),7.5(s,H,C5NH4),8.5(s,H,C5NH4),8.9(s,2H,NH2)。
Claims (7)
4.权利要求I的化合物或其药学上可接受的盐,如与下列酸形成的盐:盐酸、氢溴酸、硫酸、碳酸、柠檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、马来酸、甲磺酸、苯磺酸、对甲苯磺酸或阿魏酸。
5.权利要求I的化合物或其药学上可接受的盐在制备具有凝血酶抑制作用和抗ADP诱导的血小板聚集双重功效的药物。
小板聚集双重功效的药物。
6.权利要求I的化合物或其药学上可接受的盐,其中具有凝血酶抑制作用和抗ADP诱导的血小板聚集双重功效药物的用途。
7.权利要求6的用途,其中血管血栓栓塞性疾病可以是静脉血栓栓塞性疾病或动脉血栓栓塞性疾病。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310577411.2A CN103554087A (zh) | 2013-11-19 | 2013-11-19 | 达比加群衍生物、及其制备方法和抗血栓用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310577411.2A CN103554087A (zh) | 2013-11-19 | 2013-11-19 | 达比加群衍生物、及其制备方法和抗血栓用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103554087A true CN103554087A (zh) | 2014-02-05 |
Family
ID=50008489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310577411.2A Pending CN103554087A (zh) | 2013-11-19 | 2013-11-19 | 达比加群衍生物、及其制备方法和抗血栓用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103554087A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016019848A1 (zh) * | 2014-08-06 | 2016-02-11 | 四川海思科制药有限公司 | 一种达比加群硫酯衍生物及其制备方法和在药学上的用途 |
RU2595238C1 (ru) * | 2015-05-18 | 2016-08-20 | Галина Александровна Суханова | Способ лечения подострых венозных тромбозов различной локализации |
CN107739383A (zh) * | 2016-12-23 | 2018-02-27 | 上海美悦生物科技发展有限公司 | 一种达比加群环状衍生物的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102875533A (zh) * | 2012-11-06 | 2013-01-16 | 中国药科大学 | 达比加群衍生物、其制法及抗血栓用途 |
-
2013
- 2013-11-19 CN CN201310577411.2A patent/CN103554087A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102875533A (zh) * | 2012-11-06 | 2013-01-16 | 中国药科大学 | 达比加群衍生物、其制法及抗血栓用途 |
Non-Patent Citations (1)
Title |
---|
XIAO-ZHI YANG,ET AL.,: "Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016019848A1 (zh) * | 2014-08-06 | 2016-02-11 | 四川海思科制药有限公司 | 一种达比加群硫酯衍生物及其制备方法和在药学上的用途 |
CN107027308A (zh) * | 2014-08-06 | 2017-08-08 | 四川海思科制药有限公司 | 一种达比加群硫酯衍生物及其制备方法和在药学上的用途 |
RU2595238C1 (ru) * | 2015-05-18 | 2016-08-20 | Галина Александровна Суханова | Способ лечения подострых венозных тромбозов различной локализации |
CN107739383A (zh) * | 2016-12-23 | 2018-02-27 | 上海美悦生物科技发展有限公司 | 一种达比加群环状衍生物的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106928206B (zh) | 醛基类化合物及其制法和用途 | |
CN105849109B (zh) | 取代的氧代吡啶衍生物 | |
JP6715852B2 (ja) | 長時間作用型dpp−iv阻害剤とする置換のアミノ六員飽和ヘテロ脂環化合物 | |
EP3048108B1 (en) | Thienopiperidine derivative and use thereof | |
CN102875529B (zh) | 达比加群的酯衍生物及其制备方法 | |
BR112016003040B1 (pt) | Compostos inibidores bicíclicos de calicreína plasmática, composições farmacêuticas compreendendo os mesmos e seus usos | |
KR20160064100A (ko) | 치환된 페닐알라닌 유도체 | |
EP3049410A1 (de) | Substituierte phenylalanin-derivate als faktor xia modulatoren | |
RU2379288C2 (ru) | Новые производные пирролидин-3,4-дикарбоксамида | |
CN107428689A (zh) | 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物 | |
CN103159736A (zh) | 取代的吡唑激酶抑制剂 | |
CN103554087A (zh) | 达比加群衍生物、及其制备方法和抗血栓用途 | |
CN102225940A (zh) | 一种苯甲酸异山梨醇酯类化合物、其制备方法及医药用途 | |
CN109963561A (zh) | 可用作二酰基甘油酯o-酰基转移酶2的抑制剂的吲哚衍生物 | |
CN105732595A (zh) | 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 | |
CN103420985B (zh) | 作为前药的达比加群酯衍生物及其制备方法和用途 | |
CN107556316B (zh) | 含桥环的咪唑衍生物 | |
CN112010774B (zh) | FXIa凝血因子抑制剂、其药物组合物和用途 | |
CN107922448A (zh) | 一种氘代噻吩并哌啶衍生物、制备方法及其应用 | |
CN101812025B (zh) | 吡嗪芳酸醚类化合物、制备方法和医药应用 | |
CN103420994B (zh) | 作为前药的达比加群酯衍生物及其制备方法和用途 | |
CN103420984A (zh) | 作为前药的达比加群酯衍生物及其制备方法和用途 | |
CN103420982B (zh) | 达比加群酯衍生物及其制备方法和用途 | |
CN109970737B (zh) | 一种苯并咪唑吡啶盐类化合物及其合成方法 | |
CN102993175B (zh) | 达比加群的酯衍生物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140205 |
|
WD01 | Invention patent application deemed withdrawn after publication |